Education
About Us
Working with TipRanks
Follow Us
MicroPort NeuroTech Limited (HK:2172)
:2172
RESEARCH TOOLSreports
2172 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$6.21 - HK$15.24
Previous CloseN/A
Volume491.15K
Average Volume (3M)7.98M
Market Cap
HK$7.66B
Enterprise ValueHK$9.75B
Total Cash (Recent Filing)HK$995.06M
Total Debt (Recent Filing)¥37.12M
Price to Earnings (P/E)27.5
Beta0.94
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-Date
Jul 02, 2025Dividend Yield2.61%
Share Statistics
EPS (TTM)0.47
Shares Outstanding584,595,600
10 Day Avg. Volume16,133,481
30 Day Avg. Volume7,977,443
Financial Highlights & Ratios
PEG Ratio2.39
Price to Book (P/B)7.12
Price to Sales (P/S)0.00
P/FCF Ratio59.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
MicroPort NeuroTech Limited News
PremiumCompany Announcements
MicroPort NeuroTech Announces 2025 Annual General Meeting Agenda
PremiumCompany Announcements
MicroPort NeuroTech Engages in Strategic Wealth Management Subscription
PremiumCompany Announcements
MicroPort NeuroTech Limited Grants Share Options to Boost Employee Engagement
PremiumCompany Announcements
MicroPort NeuroScientific Announces Final Dividend with Scrip Option
PremiumCompany Announcements
MicroPort NeuroTech Achieves Strong Financial Growth in 2024
PremiumCompany Announcements
MicroPort NeuroScientific Projects Significant Profit GrowthOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.13%
Mutual Funds
― Other Institutional Investors
99.56% Public Companies and
Individual Investors
2172 FAQ
What was MicroPort NeuroTech Limited’s price range in the past 12 months?
MicroPort NeuroTech Limited lowest stock price was HK$6.21 and its highest was HK$15.24 in the past 12 months.
What is MicroPort NeuroTech Limited’s market cap?
MicroPort NeuroTech Limited’s market cap is HK$7.66B.
When is MicroPort NeuroTech Limited’s upcoming earnings report date?
MicroPort NeuroTech Limited’s upcoming earnings report date is Aug 27, 2025 which is in 70 days.
How were MicroPort NeuroTech Limited’s earnings last quarter?
MicroPort NeuroTech Limited released its earnings results on Mar 26, 2025. The company reported HK$0.205 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.205.
Is MicroPort NeuroTech Limited overvalued?
According to Wall Street analysts MicroPort NeuroTech Limited’s price is currently Overvalued.
Does MicroPort NeuroTech Limited pay dividends?
MicroPort NeuroTech Limited pays a Annually dividend of HK$0.188 which represents an annual dividend yield of 2.61%. See more information on MicroPort NeuroTech Limited dividends here
What is MicroPort NeuroTech Limited’s EPS estimate?
MicroPort NeuroTech Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MicroPort NeuroTech Limited have?
MicroPort NeuroTech Limited has 584,595,600 shares outstanding.
What happened to MicroPort NeuroTech Limited’s price movement after its last earnings report?
MicroPort NeuroTech Limited reported an EPS of HK$0.205 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.97%.
Which hedge fund is a major shareholder of MicroPort NeuroTech Limited?
Currently, no hedge funds are holding shares in HK:2172
MicroPort NeuroTech Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
79.01%
12-Months-Change
Fundamentals
Return on Equity
15.22%
Trailing 12-Months
Asset Growth
0.70%
Trailing 12-Months
Company Description
MicroPort NeuroTech Limited
MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. The company also provides APOLLO, an intracranial arterial stent system to treat intracranial atherosclerotic disease; and Bridge, a rapamycin target eluting vertebral artery stent system to treat cerebral atherosclerotic stenosis. In addition, it offers Neurohawk, a stent thrombectomy device; Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke. The company was founded in 2004 and is headquartered in Shanghai, the People's Republic of China.
Technical Analysis
Huatai Securities Co
―
Wuxi Biologics (Cayman)
―
Peijia Medical Ltd.
―
Vincent Medical Holdings Limited
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―